GLP-1 weight loss skin changes have become a commercial target for the beauty industry. A wire report published on 21 October 2026 says L’Oréal, Natura and Galderma are testing or developing products aimed at the facial volume loss and sagging that some people notice after rapid weight loss on GLP-1 drugs. The report describes testing and development, not finished launches, and none of the three companies named a new product, a launch date or an investment figure. This article sets out what is known, what the one published company study shows and where the evidence is thin. It is general information and not medical advice.
GLP-1 weight loss skin changes: key takeaways
- Galderma, L’Oréal and Natura are each reported to be working on the issue, through testing and development and not through named launches.
- Galderma sells Sculptra and Restylane; the report says these are not approved specifically for GLP-1 users, and that L’Oréal owns about 20% of Galderma.
- Experts quoted say the changes are linked to rapid weight loss and other factors, not to the drugs breaking down collagen.
- Galderma’s own nine-month study was open-label, had no control group and did not state how many people took part.
- Market figures quoted are forecasts, including a BCG estimate that clinical treatment revenue could grow from about $700 million to $2 billion in five years.
What the report says about GLP-1 weight loss skin changes
According to the wire report of 21 October 2026, Galderma ran a study last year on how some existing treatments perform on skin changes linked to GLP-1 drugs. Anne-Cecile Chevrier, its global head of injectable aesthetics, said sagginess and loss of firmness are concerns. Delphine Viguier-Hovasse, L’Oréal’s chief innovation and prospective officer, said the company is testing products on GLP-1 users in separate studies. Manuel Krauss, chief innovation and R&D officer at Natura, said the Brazilian company is testing existing products with GLP-1 users and developing a new generation of treatments, and that future innovation may combine formats such as supplements and ingestibles.
Three companies in GLP-1 weight loss skin changes
This section is our reading of the report. Galderma is the furthest along in public evidence, because it already sells injectable products used by clinicians and has published results from a study of them in people on weight-loss drugs. L’Oréal and Natura are described at an earlier stage: testing, with no products named. The report notes that headlines about launches go further than the body of the article, which describes testing and development. We therefore treat any product launch as unannounced.
What Galderma’s nine-month study shows
In its Galderma’s release on its nine-month study, dated July 2025, Galderma described a Phase IV, multicentre, open-label study at two U.S. sites in patients with facial volume loss after treatment with one of four GLP-1 receptor agonist brands. The protocol combined Sculptra with Restylane Lyft or Restylane Contour at the first visit, a second Sculptra treatment at week four and an optional third at week eight. The company reported that 85.7% of participants said their face looked less gaunt or sunken, that 91.4% would recommend the regimen, and that no treatment-related adverse events were reported. These are the company’s figures.
Limits of the GLP-1 weight loss skin changes evidence
The study was sponsored and reported by the manufacturer, was open-label with no control group, and the release does not state the number of participants or the statistical methods. The nine-month results are cited as data on file and not a peer-reviewed paper, and the main outcomes are satisfaction and appearance ratings. Those features mean the results show what participants and raters reported, but they cannot show with certainty that the treatment caused the improvement or how it compares with no treatment.
Why GLP-1 weight loss skin changes happen, according to experts
The experts quoted in the wire report attribute facial volume loss mainly to rapid weight loss, not to a direct effect of the drugs. Beibei Du-Harpur, a consultant dermatologist at King’s College London, said the term Ozempic face is misleading and that the drugs do not break down collagen. Heidi Young, a physician associate, said the cause is multifactorial. The report lists other contributors, including age-related collagen decline, loss of oestrogen in menopausal women and poor nutrition in some patients, and notes that research is limited because most female patients are peri- or postmenopausal.
Creams or injectables for GLP-1 weight loss skin changes?
The report says creams act on the surface layers of skin and cannot reposition deeper fat pads, while injectables reach deeper and are described as working better, although the volume is lost in the fat layer below the dermis. Dr Graeme Glass of LYMA said creams can help to a certain extent but cannot change the ligamental structure of the face. Our reading is that this explains why Natura points to supplements and other formats, but no evidence for any such product was presented.
The market numbers behind GLP-1 weight loss skin changes
The report cites Pfizer’s estimate that the obesity drug market could reach $150 billion in annual sales by 2030, and BCG’s 2025 estimate that clinical treatment revenue could grow from about $700 million to $2 billion over five years. By our subtraction, that is an increase of about $1.3 billion. A 2024 Medical Insight report found that 53% of U.S. aesthetics clinics expect new patients from prescription weight-loss drugs and 43% expect more demand for treatments for drug-induced facial changes. A consultancy brief on the GLP-1 beauty opportunity makes similar arguments, but it comes from a firm that sells advisory services, so treat its projections as opinion.
What is not disclosed
- Any named L’Oréal or Natura product, launch date or investment.
- The number of participants in Galderma’s nine-month study.
- Peer-reviewed results for any product aimed at GLP-1 weight loss skin changes.
- Regulatory approvals specific to people on GLP-1 drugs.
Risks and caveats on GLP-1 weight loss skin changes
- Company-reported results are not independent evidence.
- Satisfaction ratings do not measure long-term outcomes or safety in every patient.
- Market forecasts differ by source and are estimates.
- Anyone considering injectables should speak to a qualified clinician, and this article is not medical advice.
In our assessment, the clearest takeaway on GLP-1 weight loss skin changes is that interest from big beauty groups is real while the evidence for products aimed at this group is still early, so announcements should be read as testing and not as proven solutions. See also Bayer GLP-1 India Plan: Eyes 3x Revenue by 2030. More in our pharmaceutical coverage.
What to watch next on GLP-1 weight loss skin changes
- Named product launches from L’Oréal or Natura.
- Peer-reviewed publication of the Galderma data.
- Controlled studies comparing treatments with no treatment.
Frequently asked questions
What are GLP-1 weight loss skin changes?
They are changes some people notice after rapid weight loss on GLP-1 drugs, such as a hollowed face and looser skin. Experts quoted link them to the speed of weight loss and other factors.
Are Sculptra and Restylane approved for GLP-1 users?
The wire report says the products are not approved specifically for GLP-1 users, although clinicians market them to such patients.
Do GLP-1 drugs break down collagen?
A dermatologist quoted in the report said they do not, and that Ozempic face is a misleading term.
How we reported this: we relied on a wire report of 21 October 2026, Galderma’s release on its study and a consultancy brief, and we have flagged company and advisory claims. Our arithmetic and readings are labelled. Last updated: 21 October 2026. This article is news reporting and not medical advice.